Third Rock Ventures V, L.P. sold $744K of RAPP
Third Rock Ventures V, L.P. sold 18,572 shares of Rapport Therapeutics, Inc. (RAPP) at $40.05 ($0.74M total) on 2026-05-26 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The newest disclosed fact is the specific open-market sale size, price, and post-transaction holdings by a 10% owner under a pre-arranged 10b5-1 plan.
Market read
Traders may monitor for follow-on insider selling, but there is no new company-specific fundamental catalyst in the text.
What to watch
The filing does not state motivations; traders should check whether this is part of a larger, repeated selling program or a one-off tranche.
Background
The article is a SEC Form 4 insider transaction disclosure for Rapport Therapeutics, Inc. (RAPP).
Ticker impact
Third Rock Ventures V, L.P., a 10% owner, sold 18,572 RAPP shares in an open-market transaction under a 10b5-1 plan.
Likely limited near-term impact; any effect would be sentiment-driven and should fade unless follow-on selling is disclosed.
Form 4 reports a completed sale with disclosed price and size, but it does not include new operating, regulatory, or clinical information for Rapport Therapeutics.
Market effects
Minimal. Insider-sale Form 4s typically do not reset sector expectations for biotech unless tied to adverse events.
None indicated.
None indicated.
Counterpoint
A 10b5-1 plan sale can be routine and pre-scheduled, so it may not reflect new negative information.
Key entities
- issuerRapport Therapeutics, Inc.
Subject of the Form 4 insider transaction disclosure.
- 10% ownerThird Rock Ventures V, L.P.
Reported open-market sale of RAPP shares under a 10b5-1 plan.
